Please login to the form below

Not currently logged in

Summit appoints Pfizer/Bayer veteran as CMO

David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile

Summit David RoblinIndustry veteran Dr David Roblin has joined the Oxford, UK-based drug development and discovery company Summit as its chief medical officer.

Dr Roblin has years of senior research experience at major pharma firms, including serving as head of research, site director and chief medical officer for Europe R&D during a spell with Pfizer.

He was also head of ant-infectives at Bayer, where he led the development of several antiobiotics, including Avelox (moxifloxacin) and Cipro (ciprofloxacin).

This experience in anti-infectives will prove useful at Summit, with the company's research efforts including the development of treatments for C difficile infection in addition to potential thereapies for Duchenne muscular dystrophy.

"David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines,” said Summit's CEO Glyn Edwards.

“As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to their successful development."

13th June 2013


Featured jobs

Subscribe to our email news alerts


Add my company

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...